Ebatid IV infusion

Dexa Medica

Ingredients in every 100 ml

Eptifibatide 75 mg

Each package contains

1 bottle of 100 ml

Other details

Dosage form:Intravenous infusion
Flavour: None

W.H.O. classification

ATC Level 1: B - Blood and blood forming organs
ATC Level 2: B01 - Antithrombotic Agents
ATC Level 3: B01A - Antithrombotic Agents

Warnings

Pregnancy

CONSULT YOUR DOCTORSafety of this item for use during pregnancy has not been established. Please consult your doctor.

Lactation

CONSULT YOUR DOCTORSafety of this item for use during lactation has not been established. Please consult your doctor.

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

CONSULT YOUR DOCTORSafety of this item for use while operating heavy machinery has not been established. Please consult your doctor.

Available in

Indonesia

Dosage information

18 YEARS OLD AND ABOVE
Acute coronary syndrome (Unstable angina or Non-Q-wave myocardial infarction) with creatinin clearance ≥ 50 ml/minute: intravenous bolus 180 µg/kg, followed by continuous infusion 2.0 µg/kg/minute until hospital discharge or initiation of coronary artery bypass graft, up to 72 hours.

Acute coronary syndrome (Unstable angina or Non-Q-wave myocardial infarction) with creatinin clearance ≥30 – <50 ml/minute: intravenous bolus 180 µg/kg, followed by continuous infusion 1.0 µg/kg/minute until hospital discharge or initiation of coronary artery bypass graft, up to 72 hours. Patients undergoing Percutaneous Coronary Intervention (PCI) with creatinin clearance ≥ 50 ml/minute: intravenous bolus 180 µg/kg before PCI, followed by continuous infusion 2.0 µg/kg/minute and a second 180 µg/kg bolus, 10 minutes after the first bolus injection. Infusion should be continued until hospital discharge or maximum of 18-24 hours post-PCI, whichever comes first. A minimum of 12 hours of infusion is recommended. Patients undergoing Percutaneous Coronary Intervention (PCI) with creatinin clearance ≥30 – <50 ml/minute: intravenous bolus 180 µg/kg before PCI, followed by continuous infusion 1.0 µg/kg/minute and a second 180 µg/kg bolus, 10 minutes after the first bolus injection. Infusion should be continued until hospital discharge or maximum of 18-24 hours post-PCI, whichever comes first. A minimum of 12 hours of infusion is recommended. 0 TO 18 YEARS OLD
Safety and effectiveness have not been studied.

PATIENTS WITH ACUTE CORONARY SYNDROME
– Acute coronary syndrome (Unstable angina or Non-Q-wave myocardial infarction) with creatinin clearance ≥ 50 ml/minute:
patients weighing more than 121 kg should receive a maximum bolus of 22.6 mg followed by a maximum infusion rate of 15 mg per hour

– Acute coronary syndrome (Unstable angina or Non-Q-wave myocardial infarction) with creatinin clearance ≥30 – <50 ml/minute: patients weighing more than 121 kg should receive a maximum bolus of 22.6 mg followed by a maximum infusion rate of 7.5 mg per hour PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)
– PCI with creatinin clearance ≥ 50 ml/minute:
patients weighing more than 121 kg should receive a maximum of 22.6 mg per bolus followed by a maximum infusion rate of 15 mg per hour.

– with creatinin clearance ≥30 – <50 ml/minute: patients weighing more than 121 kg should receive a maximum of 22.6 mg per bolus followed by a maximum infusion rate of 7.5 mg per hour. CORONARY ARTERY BYPASS GRAFT SURGERY
In patients who undergo coronary artery bypass graft surgery, eptifibatide infusion should be discontinued prior to surgery.

Indication

– For the treatment of patients with acute coronary syndrome (Unstable Angina (UA)/Non-Q Wave Myocardial Infarction (NQMI)), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). In this setting, eptifibatide has been shown to decrease the rate of a combined endpoint of death or new myocardial infarction.
– For the treatment of patients undergoing PCI, including those undergoing intracoronary stenting. In this setting, eptifibatide has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction, or need for urgent intervention.

Disclaimer

The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for informational purposes only. This tool may not cover all possible drug interactions or all warnings or alerts. Please check with a physician if you have health questions or concerns about interactions or go to the appropriate government authority for a comprehensive list of medical warnings. Although we attempt to provide accurate and up-to-date information, no guarantee is made to that effect.

All of the content present on this website, including written text, photographs, videos, graphics, and other resources we might include (these will fall under the collective term of “website”), is meant to educate and should not be perceived as a substitution for professional medical advice, diagnosis or treatment. You should not resort to the website information to arrive at a diagnosis or treatment solution for your health problems or various medical conditions. It does not replace medical care, provided by a medical specialist. In the situation, you have specific symptoms and you might suspect that you are suffering from a medical problem, it is for the best to consult your physician.